The FDA approved the first IV ferric carboxymaltose injection for iron deficiency in adults with heart failure to improve exercise capacity, according to a press release from American Regent.The IV iron injection (Injectafer, Daiichi Sankyo/American Regent) is approved for people with New York Heart Association class II/III HF, defined as patients with a slight or marked limitation of their
This new indication for ferric carboxymaltose injection marks the first FDA approval of an intravenous iron replacement therapy for adult patients with heart failure, the company said.
Endo Announces Publication of Phase 3 Qwo (collagenase clostridium histolyticum-aaes) Data in Peer-Reviewed Dermatologic Surgery finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.